Citalift (Citalift)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceCitalopramCitalopram
Similar drugsTo uncover
  • Oprah
    pills inwards 
    AKTAVIS, LTD.     Russia
  • PRAM®
    pills inwards 
    Lannacher Heilmittel GmbH     Austria
  • Siozam
    pills inwards 
    VEROPHARM SA     Russia
  • Uorop®
    pills inwards 
    Laboratorios Bago S.A.     Argentina
  • Cipramil
    pills inwards 
    H. Lundbeck A / S     Denmark
  • Citalift
    pills inwards 
    Ranbaxy Laboratories Limited     India
  • Citalon®
    pills inwards 
    Sandoz d.     Slovenia
  • Citalopram
    pills inwards 
    ALSI Pharma, ZAO     Russia
  • Citalopram
    pills inwards 
    Aurobindo Pharma Co., Ltd.     India
  • Citol®
    pills inwards 
    NANOLEC, LTD.     Russia
    • Dosage form: & nbspfilm-coated tablets
    Composition:

    1 tablet contains:

    Active ingredient:

    for a dose of 20 mg: citalopram hydrobromide 25 mg, equivalent to citalopram 20 mg;

    for a dose of 40 mg: citalopram hydrobromide 50 mg, equivalent to citalopram 40 mg.

    Inactive Ingredients:

    lactoses monohydrate, microcrystalline cellulose (avicel PH 101), cellulose microcrystalline (avicel PH 102), corn starch, copovidone, croscarmellose sodium magnesium stearate, purified water*.

    Film sheath:

    Dyeing powder white 20H58983, purified water *.

    The composition of the dye dropping white 20N58983: hypromellose (2910 5cP), titanium dioxide, Propylene glycol, giprolase, talc.

    * - evaporates in the production process

    Description:

    Citalift 20 mg: white to almost white, round biconvex tablets covered with a film sheath, engraved "20" on one side and risky on the other side.

    Citalift 40 mg: white to almost white, round biconvex tablets covered with a film sheath, with an engraving "40" on one side and a risk on the other side.

    Pharmacotherapeutic group:antidepressant
    ATX: & nbsp

    N.06.A.B.04   Citalopram

    Pharmacodynamics:

    Antidepressant, selective serotonin reuptake inhibitor. The antidepressant effect usually develops after 2-4 weeks of therapy. Citalopram has little or no ability to bind to a variety of receptors, including histamine, m-cholinergic receptors and adrenoreceptors. Sedation is absent.

    To a very small extent inhibits cytochrome P450IID6, therefore does not interact with drugs metabolized by this isoenzyme.

    Citalopram does not affect the conduction system of the heart and blood pressure, does not change hematologic parameters, liver and kidney function, does not cause weight gain.

    Pharmacokinetics:

    Bioavailability of citalopram is 80%, almost independent of food intake.

    TFROMmOh when ingested - 4 hours. Connection with plasma proteins - no more than 80%. The plasma is present unchanged. The volume of distribution is 12 l / kg. The concentration in the plasma varies linearly. Css with a daily one-time reception is established after 7 days. At doses of 10-60 mg / day pharmacokinetic parameters have a linear dependence. Penetrates into breast milk.

    Metabolized by demethylation, deamination and oxidation involving cytochrome P450 (isoenzymes. CYP3A4 and CYP2C19) c formation of less pharmacologically active metabolites.

    T1/2 -1.5 days. It is excreted by the kidneys and through the intestines.

    Indications:

    - Depression of different etiology and structure;

    - panic disorder with / without agoraphobia;

    - obsessive-compulsive disorder (OCD).

    Contraindications:

    - Hypersensitivity to the drug;

    - simultaneous administration with MAO inhibitors (including the period within 14 days after their cancellation), sumatriptan and other serotonergic drugs;

    - children under 18 years of age (efficacy and safety of use not established).

    Carefully:

    Drug dependence (including history), hepatic and / or renal failure, mania, hypomania, convulsive seizures, pregnancy, lactation period, elderly age.

    Pregnancy and lactation:

    Safety of the use of the Citalift during pregnancy and lactation is not established. The use of the drug is justified only in those cases when the potential benefit of therapy for the mother exceeds the possible risk for the fetus and the child.

    AT experimental research there was no teratogenic effect and no effect of citalopram on reproductive function and perinatal development of the fetus.

    Dosing and Administration:

    Citalift can be taken regardless of food intake, at any time of the day.

    The drug is administered orally once a day.

    When depression and obsessive-compulsive disorder the drug is prescribed in a dose of 20 mg per day. Depending on the individual reaction, the patient and the severity of the disease, the dose can be increased to a maximum of 60 mg per day.

    When panic disorder during the first week of treatment, the recommended dose is 10 mg per day, then the dose is increased to 20 mg per day. Depending on the individual response of the patient to the drug, the daily dose may be increased in the future. The maximum dose is 60 mg per day.

    In elderly patients the recommended dose is 20 mg per day. If necessary, the dose can be increased to the maximum - 40 mg per day.

    Patients with severe hepatic impairment the drug is prescribed in the minimum recommended doses.

    Side effects:

    From the nervous system: rarely asthenia, excessive fatigue, drowsiness or insomnia, anxiety, tremor, agitation, amnesia, apathy, extrapyramidal symptoms, mood changes, aggressive behavior, hallucinations, depersonalization, emotional lability, euphoria, mania, hypomania, panic behavior, paranoid reaction, psychosis , serotonin syndrome (agitation, confusion, diarrhea, hyperthermia, hyperreflexia, ataxia, tremor, increased sweating, agitation, uncontrolled behavior).

    From the side of the digestive tract: rarely - dry mouth, nausea, vomiting, hypersalivation, flatulence, diarrhea, abdominal pain, anorexia.

    From the cardiovascular system: rarely - bradycardia, lowering of arterial pressure, orthostatic hypotension, arrhythmia.

    On the part of the organs of hematopoiesis: rarely - thrombocytopenia, bleeding.

    From the sense organs: rarely - mydriasis, paresis of accommodation, a taste disorder.

    From the side of the reproductive system: violation of sexual function: violation of ejaculation, decreased libido, impotence, menstrual irregularities.

    Allergic reactions: skin rash, rarely - epidermal necrosis, rhinitis, sinusitis.

    Other: rarely - hyperthermia, polyuria, mastodonia, galactorrhea, hyponatremia, violation of urination, arthralgia, myalgia, yawning, gnashing of teeth, increase or decrease in body weight, dyspnea.

    Overdose:

    Symptoms: drowsiness, coma, violations of articulation, episodically - large convulsive seizures (grand mal), sinus tachycardia, sometimes nodal rhythm, increased sweating, nausea, vomiting, cyanosis, hyperventilation of the lungs. The clinical picture is not characteristic.

    Treatment: it is necessary to rinse the stomach as soon as possible after taking the drug. Conduct symptomatic and supportive therapy. It is recommended to monitor the patient's condition. There is no specific antidote.

    Interaction:

    With the simultaneous use of citalift and MAO inhibitors, the development of a hypertensive crisis (serotonin syndrome) is possible.

    Because the cimetidine causes a moderate increase in the average equilibrium concentration of citalopram in the blood, in high doses they should be combined with caution.

    There was no clinically significant pharmacokinetic interaction between citalopram and phenothiazines and tricyclic antidepressants.

    Clinical studies have not revealed the pharmacodynamic interaction of citalopram with simultaneous use with benzodiazepines, neuroleptics, analgesics, cast preparations, antihypertensive agents, antihistamines, beta-blockers and other cardiotropic drugs.

    There was no interaction of citalopram with ethanol.

    The effects of sumatriptan and other serotonergic drugs may be intensified by citalopram.

    To an insignificant degree inhibits cytochrome CYP2D6, in connection with which weakly interacts with drugs metabolized with his participation.

    With a simultaneous appointment with warfarin, prothrombin time increases by 5%.

    Special instructions:

    Treatment with MAO inhibitors can be started 7 days after cessation of the Citalift.

    With moderate disorders of kidney function, correction of the dosing regimen is not required.

    When the phase of depression is reversed and the manic state develops, the citalift should be canceled.

    Effect on the ability to drive transp. cf. and fur:

    Citalift does not reduce the ability to think activity and the speed of psychomotor reactions. However, it should be borne in mind that in patients with depression, there is often a decrease in the ability to concentrate, which can be exacerbated by the use of psychotropic drugs. Assigning the Citalift in depression, the patient should be warned about a possible decrease in the ability to concentrate and the speed of psychomotor reactions when driving a car and working with mechanisms.

    Form release / dosage:Tablets, film-coated, 20 mg and 40 mg.
    Packaging:

    14 tablets in a blister of aluminum foil, coated with PVC / PVDC film; 1, 2, 4 or 7 blisters with instructions for use in a cardboard pack.

    Storage conditions:

    Store at a temperature not exceeding 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-007074/08
    Date of registration:04.09.2008
    The owner of the registration certificate:Ranbaxy Laboratories LimitedRanbaxy Laboratories Limited India
    Manufacturer: & nbsp
    Representation: & nbspRABBAYS LABORATORY LIMITEDRABBAYS LABORATORY LIMITED
    Information update date: & nbsp27.09.2015
    Illustrated instructions
      Instructions
      Up